CompaniesGenetix Biotherapeutics
Genetix Biotherapeutics logo

Genetix Biotherapeutics

active
Somerville, MA, United States
Founded 1992
Website
About

Gene Therapy, Cellular Extraction & Reintroduction

Areas of Focus

Categories

Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapyBoston & New England
Team (6)
Adrian Chaisson
Adrian Chaisson
Chief of Staff
Genetix Biotherapeutics
team_member
Brian Riley
Brian Riley
President & Chief Technical Officer
Genetix Biotherapeutics
executive
David Meek
David Meek
Chief Executive Officer
Genetix Biotherapeutics
executive
Joanne Lager
Joanne Lager
MD, Chief Medical Officer
Genetix Biotherapeutics
executive
Tom Klima
Tom Klima
Chief Commercial & Operating Officer
Genetix Biotherapeutics
team_member
Wendy DiCicco
Wendy DiCicco
Chief Financial Officer
Genetix Biotherapeutics
executive
Clinical Trials (19)
View all

Total Trials

19

As Lead Sponsor

14

As Collaborator

5

Total Enrollment

1,968

By Phase

PHASE2: 2PHASE3: 4EARLY_PHASE1: 1PHASE1: 1PHASE1/PHASE2: 3PHASE2/PHASE3: 1

By Status

COMPLETED: 9ACTIVE_NOT_RECRUITING: 5RECRUITING: 2TERMINATED: 2ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline19 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
Today
NCT02151526
NCT01896102
NCT02633943
NCT02140554
NCT02658929
NCT02698579
NCT02906202
NCT03131934
NCT04293185
NCT04628585
NCT06271512
NCT06224413
Hover over trial bars to see details

Recent Trials

NCT06224413Lead Sponsor
A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel
N/ARecruiting
120 participants
Started: Mar 27, 2024 · Completed: Dec 30, 2047
NCT06271512Lead Sponsor
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
N/ARecruiting
150 participants
Started: Jan 23, 2024 · Completed: Dec 31, 2043
NCT05353647Collaborator
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
PHASE2Active, not recruiting
25 participants
Started: Jul 12, 2022 · Completed: Jul 31, 2027
NCT05445128Collaborator
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
PHASE2Terminated
1 participants
Started: Jun 24, 2022 · Completed: Feb 2, 2023
NCT04628585Lead Sponsor
Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
N/AEnrolling by invitation
85 participants
Started: Oct 21, 2020 · Completed: Jan 31, 2038
View all 19 trials →
Locations (1)
Headquarters
Somerville, MA, United States
Map

Loading map...